{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:40:27Z","timestamp":1790250027250,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cellsig.2022.110497","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:44:53Z","timestamp":1666010693000},"page":"110497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy"],"prefix":"10.1016","volume":"101","author":[{"given":"Rui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiying","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cellsig.2022.110497_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110497_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019 [J]","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110497_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CCO.0000000000000592","article-title":"Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer [J]","volume":"32","author":"Pirker","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2022.110497_bb0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1042\/BST20191055","article-title":"Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis [J]","volume":"48","author":"Lev","year":"2020","journal-title":"Biochem. Soc. Trans."},{"issue":"7","key":"10.1016\/j.cellsig.2022.110497_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrclinonc.2010.64","article-title":"Targeted therapy in non-small-cell lung cancer--is it becoming a reality? [J]","volume":"7","author":"Janku","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.cellsig.2022.110497_bb0030","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1158\/1535-7163.MCT-12-0615","article-title":"Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib [J]","volume":"11","author":"Acquaviva","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.cellsig.2022.110497_bb0035","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccr.2010.11.033","article-title":"ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time [J]","volume":"18","author":"Gerber","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.cellsig.2022.110497_bb0040","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer [J]","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cellsig.2022.110497_bb0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer [J]","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.cellsig.2022.110497_bb0050","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20030286","article-title":"MIF signal transduction initiated by binding to CD74 [J]","volume":"197","author":"Leng","year":"2003","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2022.110497_bb0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers [J]","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2022.110497_bb0060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/DDDT.S19045","article-title":"Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond [J]","volume":"5","author":"Ou","year":"2011","journal-title":"Drug. Des. Devel. Ther."},{"issue":"10","key":"10.1016\/j.cellsig.2022.110497_bb0065","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J]","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellsig.2022.110497_bb0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-319-91442-8_4","article-title":"Crizotinib [J]","volume":"211","author":"Heigener","year":"2018","journal-title":"Recent Results Cancer Res."},{"issue":"6","key":"10.1016\/j.cellsig.2022.110497_bb0075","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.21037\/tlcr-20-331","article-title":"How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC) [J]","volume":"9","author":"Xia","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"14","key":"10.1016\/j.cellsig.2022.110497_bb0080","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer [J]","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.cellsig.2022.110497_bb0085","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers [J]","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.cellsig.2022.110497_bb0090","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00280-019-03902-6","article-title":"Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer [J]","volume":"84","author":"Roys","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cellsig.2022.110497_bb0095","first-page":"583","article-title":"Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition [J]","volume":"5","author":"Facchinetti","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.cellsig.2022.110497_bb0100","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-14-1350","article-title":"Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer [J]","volume":"21","author":"Song","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2022.110497_bb0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2018.02.032","article-title":"CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib [J]","volume":"422","author":"Gou","year":"2018","journal-title":"Cancer Lett."},{"issue":"3\u20134","key":"10.1016\/j.cellsig.2022.110497_bb0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.18632\/genesandcancer.136","article-title":"NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors [J]","volume":"8","author":"McGowan","year":"2017","journal-title":"Genes Cancer"},{"issue":"7605","key":"10.1016\/j.cellsig.2022.110497_bb0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer [J]","volume":"534","author":"Mertins","year":"2016","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2022.110497_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10555-008-9165-4","article-title":"Signal transduction by focal adhesion kinase in cancer [J]","volume":"28","author":"Zhao","year":"2009","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.cellsig.2022.110497_bb0125","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications [J]","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.cellsig.2022.110497_bb0130","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4161\/cbt.9.10.11434","article-title":"PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments [J]","volume":"9","author":"Tanjoni","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2022.110497_bb0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1083\/jcb.201501025","article-title":"Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway [J]","volume":"210","author":"Kim","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.cellsig.2022.110497_bb0140","first-page":"424","volume":"28","author":"Han","year":"2018","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110497_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010192","article-title":"FAK-dependent cell motility and cell elongation [J]","volume":"9","author":"Katoh","year":"2020","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.cellsig.2022.110497_bb0150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jtho.2018.04.016","article-title":"Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non-small cell lung cancer [J]","volume":"13","author":"Li","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2022.110497_bb0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/onc.2016.195","article-title":"The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids [J]","volume":"36","author":"Chiu","year":"2017","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.cellsig.2022.110497_bb0160","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbrc.2005.07.034","article-title":"A truncated FAK lacking the FERM domain displays high catalytic activity but retains responsiveness to adhesion-mediated signals [J]","volume":"334","author":"J\u00e1camo","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110497_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01009-7","article-title":"Abnormally activated OPN\/integrin \u03b1V\u03b23\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer [J]","volume":"13","author":"Fu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellsig.2022.110497_bb0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ceb.2017.01.003","article-title":"Focal adhesion kinase signaling in unexpected places [J]","volume":"45","author":"Kleinschmidt","year":"2017","journal-title":"Curr. Opin. Cell Biol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656822002595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656822002595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T06:13:08Z","timestamp":1718431988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656822002595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"alternative-id":["S0898656822002595"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110497","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110497"}}